RT Journal Article
T1 Postoperative Outcomes Within Enhanced Recovery After Surgery Protocol in Elective Total Hip and Knee Arthroplasty. POWER.2 Study: Study Protocol for a Prospective, Multicentre, Observational Cohort Study.
A1 Ripollés-Melchor, Javier
A1 Abad-Motos, Ane
A1 Logroño-Egea, Margarita
A1 Aldecoa, César
A1 García-Erce, José Antonio
A1 Jiménez-López, Ignacio
A1 Cassinello-Ogea, Concepción
A1 Marín-Peña, Oliver
A1 Ferrando-Ortolá, Carlos
A1 de la Rica, Alejandro Suárez
A1 Gómez-Ríos, Manuel A
A1 Sánchez-Martín, Rubén
A1 Abad-Gurumeta, Alfredo
A1 Casans-Francés, Rubén
A1 Mugarra-Llopis, Ana
A1 Varela-Durán, Marina
A1 Longás-Valién, Javier
A1 Ramiro-Ruiz, Álvaro
A1 Cuellar-Martínez, Ana B
A1 Ramírez-Rodríguez, José M
A1 Calvo-Vecino, José M
K1 Arthroplasty
K1 arthroplasty
K1 follow-up studies
K1 hip
K1 knee
K1 outcome and process assessment (health care)
K1 replacement
AB The number of indications for total hip replacement (THR) and total knee replacement (TKR) surgery is increasing. Enhanced recovery after surgery (ERAS) represents the next step in the evolution of standardised care. The primary aim of this study is to measure the in-hospital 30-day medical and surgical postoperative complications rate. The study's secondary aims are to determine the length of stay, 30-day mortality rate, 30-day reoperation and readmission rates, the ERAS overall compliance and predefined ERAS individual items compliance. This multicentre, prospective, observational study will include adult patients (aged >18 years) undergoing elective THR and TKR surgery. Consecutive patients undergoing surgery within the 2-month data collection period will be included. Centres that offer the THR and/or TKR surgery will be eligible to participate. The data collection will be done through an online data collection form via a secure, password-protected platform at each centre with predefined data fields. Ethical approval for this study has been obtained from the Comité de Ética de la Investigación de la Comunidad Autónoma de Aragón (C.P.-C.I. PI18/135; on 23 May 2018). It was prospectively registered on 27 June 2018, at www.clinicaltrials.gov with identification no. NCT03570944. The study will be disseminated through the SPARN-RedGERM, SEDAR, GERM and through social media. Peer-reviewed publications will be published under corporate authorship, including POWER.2 Study Group and SPARN-RedGERM.
SN 2667-677X
YR 2019
FD 2019-01-24
LK https://hdl.handle.net/10668/27366
UL https://hdl.handle.net/10668/27366
LA en
DS RISalud
RD Apr 4, 2025